We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+8.55%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
AUM
$11.4B
AUM Growth
+$476M
Cap. Flow
-$300M
Cap. Flow %
-2.64%
Top 10 Hldgs %
22.33%
Holding
2,538
New
224
Increased
309
Reduced
1,136
Closed
102

Top Sells

Rank Stock Value
1
MPLX icon
MPLX
MPLX
+$20.7M
2
AAPL icon
Apple
AAPL
+$16M
3
BSV icon
Vanguard Short-Term Bond ETF
BSV
+$15.6M
4
MSFT icon
Microsoft
MSFT
+$13M
5
WMB icon
Williams Companies
WMB
+$9.28M

Sector Composition

Rank Sector Weight
1 Technology 20.93%
2 Financials 13.29%
3 Healthcare 12.64%
4 Consumer Discretionary 11.46%
5 Industrials 9.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NPO icon
1326
Enpro
NPO
$7.12B
$761K 0.01%
7,831
GBT
1327
DELISTED
Global Blood Therapeutics, Inc.
GBT
$760K 0.01%
+21,706
New +$847K
CHRD icon
1328
Chord Energy
CHRD
$7.35B
$758K 0.01%
+7,543
New +$621K
OCDX
1329
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$758K 0.01%
35,416
PDM
1330
Piedmont Realty Trust
PDM
$1.2B
$758K 0.01%
41,047
-6,251
-13% -$116K
LGF.B
1331
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
$756K 0.01%
+41,313
New +$633K
HOUS
1332
DELISTED
Anywhere Real Estate
HOUS
$755K 0.01%
41,433
+4,359
+12% +$74.5K
FCPT icon
1333
Four Corners Property Trust
FCPT
$2.76B
$755K 0.01%
27,333
-4,292
-14% -$121K
RVNC
1334
DELISTED
Revance Therapeutics, Inc.
RVNC
$754K 0.01%
25,433
TEVA icon
1335
Teva Pharmaceuticals
TEVA
$42.6B
$750K 0.01%
75,753
BNGO icon
1336
Bionano Genomics
BNGO
$13.5M
$750K 0.01%
+170
New +$671K
ARRY icon
1337
Array Technologies
ARRY
$796M
$747K 0.01%
+47,853
New +$1.01M
CVCO icon
1338
Cavco Industries
CVCO
$4.67B
$745K 0.01%
3,353
ARI
1339
Apollo Commercial Real Estate
ARI
$886M
$744K 0.01%
46,637
-7,160
-13% -$111K
KALU icon
1340
Kaiser Aluminum
KALU
$2.99B
$742K 0.01%
6,012
MGRC icon
1341
McGrath RentCorp
MGRC
$2.94B
$740K 0.01%
9,074
FMBI
1342
DELISTED
First Midwest Bancorp Inc/IL
FMBI
$739K 0.01%
37,259
-5,851
-14% -$123K
ROIC
1343
DELISTED
Retail Opportunity Investments Corp.
ROIC
$739K 0.01%
41,820
+3,600
+9% +$63.3K
WKHS icon
1344
Workhorse Group
WKHS
$33.1M
$737K 0.01%
15
+6
+67% +$222K
CWK icon
1345
Cushman & Wakefield Ltd
CWK
$3.37B
$737K 0.01%
42,194
+5,979
+17% +$106K
AXSM icon
1346
Axsome Therapeutics
AXSM
$11.2B
$736K 0.01%
10,909
QGEN icon
1347
Qiagen
QGEN
$8.93B
$734K 0.01%
14,319
RAVN
1348
DELISTED
Raven Industries Inc
RAVN
$733K 0.01%
12,675
CENTA icon
1349
Central Garden & Pet Co Class A
CENTA
$2.41B
$732K 0.01%
18,935
CRS icon
1350
Carpenter Technology
CRS
$26.6B
$727K 0.01%
18,072

Similar funds

MetLife Investment Management's Q2 2021 Portfolio in Review

As of Q2 2021, MetLife Investment Management held 2,538 positions worth $11.4B, up 4.4% from $10.9B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

MetLife Investment Management's Q2 2021 filing shows 224 new, 309 increased, 1,136 reduced and 102 closed positions. Its largest new stake was UiPath: 142,126 shares worth $9.65M. The largest sale was MPLX, an estimated $20.7M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.

  • MetLife Investment Management's largest Q2 2021 buy was UiPath: 142,126 shares worth $9.65M.
  • MetLife Investment Management added most to State Street SPDR S&P 500 ETF Trust in Q2 2021, an estimated $24.1M increase.
  • MetLife Investment Management's biggest Q2 2021 reduction was Apple, cutting an estimated $16M.
  • MetLife Investment Management fully exited MPLX in Q2 2021, selling an estimated $20.7M.
  • MetLife Investment Management's ten largest holdings make up 22% of its $11.4B portfolio in Q2 2021.
  • MetLife Investment Management opened 224 new positions and closed 102 in Q2 2021.
  • MetLife Investment Management's portfolio value rose 4.4% quarter-over-quarter to $11.4B.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.